Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tobias F. Dreyer"'
Autor:
Bjoern F. Kraemer, Irina Hennis, Anne Karge, Anne Katrin Kraemer, Tobias F. Dreyer, Marion Kiechle, Bettina Kuschel, Holger Bronger
Publikováno v:
Molecular Medicine, Vol 28, Iss 1, Pp 1-9 (2022)
Abstract Background Thrombocytopenia is a feared complication of preeclampsia (PE) that can additionally complicate the disease course and that carries a poor prognosis. The disease mechanisms of PE on a platelet level are poorly understood and only
Externí odkaz:
https://doaj.org/article/896cfbf6d15d4ab9aa50ccb880912453
Autor:
Yueyang Liu, Weiwei Gong, Sarah Preis, Julia Dorn, Marion Kiechle, Ute Reuning, Viktor Magdolen, Tobias F. Dreyer
Publikováno v:
Life, Vol 12, Iss 10, p 1517 (2022)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with poor patient prognosis and limited therapeutic options. A lack of prognostic biomarkers and therapeutic targets fuels the need for new approaches to tackle this severe d
Externí odkaz:
https://doaj.org/article/9418a2e7d44c4ddbbfb589541e126bef
Autor:
Holger Bronger, Gabriele Multhoff, Viktor Magdolen, Ute Reuning, Marion Kiechle, Julia Dorn, Manfred Schmitt, Jürgen Ruland, Wilko Weichert, Anja K. Wege, Aurelia Noske, Alexander Hapfelmeier, Stefan Stangl, Stefanie Seitz, Wolfgang Sievert, Jil Jelsma, Daniela Schilling, Nadine Heithorst, Christoph Stange, Sabine Kuhn, Tobias F. Dreyer
Patient characteristics of the whole breast cancer cohort used for CX3CL1 expression analysis (n=250)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::294517599c0d0d4d5a2ae3dce6640ee5
https://doi.org/10.1158/2326-6066.22543890
https://doi.org/10.1158/2326-6066.22543890
Autor:
Holger Bronger, Gabriele Multhoff, Viktor Magdolen, Ute Reuning, Marion Kiechle, Julia Dorn, Manfred Schmitt, Jürgen Ruland, Wilko Weichert, Anja K. Wege, Aurelia Noske, Alexander Hapfelmeier, Stefan Stangl, Stefanie Seitz, Wolfgang Sievert, Jil Jelsma, Daniela Schilling, Nadine Heithorst, Christoph Stange, Sabine Kuhn, Tobias F. Dreyer
CX3CL1 mRNA expression is associated with improved recurrence-free, distant-metastasis free, and overall survival in human breast cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095d42e442b47dc9109ad0a4e9eb9db2
https://doi.org/10.1158/2326-6066.22543914.v1
https://doi.org/10.1158/2326-6066.22543914.v1
Autor:
Holger Bronger, Gabriele Multhoff, Viktor Magdolen, Ute Reuning, Marion Kiechle, Julia Dorn, Manfred Schmitt, Jürgen Ruland, Wilko Weichert, Anja K. Wege, Aurelia Noske, Alexander Hapfelmeier, Stefan Stangl, Stefanie Seitz, Wolfgang Sievert, Jil Jelsma, Daniela Schilling, Nadine Heithorst, Christoph Stange, Sabine Kuhn, Tobias F. Dreyer
A crucial mode of action of trastuzumab is the labeling of HER2-positive (HER2+) tumor cells for the eradication by natural killer (NK) cells, a process called antibody-dependent cellular cytotoxicity (ADCC). However, despite widespread HER2 expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7916972621b15ba7ad93f29035da6c
https://doi.org/10.1158/2326-6066.c.6550452.v1
https://doi.org/10.1158/2326-6066.c.6550452.v1
Autor:
Yueyang Liu, Weiwei Gong, Sarah Preis, Julia Dorn, Marion Kiechle, Ute Reuning, Viktor Magdolen, Tobias F. Dreyer
Publikováno v:
Life; Volume 12; Issue 10; Pages: 1517
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with poor patient prognosis and limited therapeutic options. A lack of prognostic biomarkers and therapeutic targets fuels the need for new approaches to tackle this severe d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44fd418bc907b9002a89248bc80e37df
https://mediatum.ub.tum.de/1690949
https://mediatum.ub.tum.de/1690949
Autor:
Stefanie Seitz, Tobias F. Dreyer, Christoph Stange, Katja Steiger, Rosalinde Bräuer, Leandra Scheutz, Gabriele Multhoff, Wilko Weichert, Marion Kiechle, Viktor Magdolen, Holger Bronger
Publikováno v:
British journal of cancer. 126(10)
Background Response to immune checkpoint blockade (ICB) in ovarian cancer remains disappointing. Several studies have identified the chemokine CXCL9 as a robust prognosticator of improved survival in ovarian cancer and a characteristic of the immunor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6047ef417bf30853db10000dff74e54d
https://pubmed.ncbi.nlm.nih.gov/35314795
https://pubmed.ncbi.nlm.nih.gov/35314795
Autor:
Tobias F, Dreyer, Sabine, Kuhn, Christoph, Stange, Nadine, Heithorst, Daniela, Schilling, Jil, Jelsma, Wolfgang, Sievert, Stefanie, Seitz, Stefan, Stangl, Alexander, Hapfelmeier, Aurelia, Noske, Anja K, Wege, Wilko, Weichert, Jürgen, Ruland, Manfred, Schmitt, Julia, Dorn, Marion, Kiechle, Ute, Reuning, Viktor, Magdolen, Gabriele, Multhoff, Holger, Bronger
Publikováno v:
Cancer immunology research. 9(7)
A crucial mode of action of trastuzumab is the labeling of HER2-positive (HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d377a3eaebb399028864d08ca51760ef
https://pubmed.ncbi.nlm.nih.gov/33906866
https://pubmed.ncbi.nlm.nih.gov/33906866